Elikem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.25 M
- Paid Up Capital ₹ 1.25 M
- Company Age 32 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.86 Cr
- Satisfied Charges ₹ 1.35 Cr
- Revenue Growth 14.15%
- Profit Growth 41.95%
- Ebitda 48.50%
- Net Worth 25.24%
- Total Assets 13.76%
About Elikem Pharmaceuticals
Elikem Pharmaceuticals Private Limited (EPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 August 1992 and has a history of 32 years and six months. Its registered office is in Gandhi Nagar, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 M and a paid-up capital of Rs 1.25 M.
The company currently has active open charges totaling ₹3.86 Cr. The company has closed loans amounting to ₹1.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pratik Patel, Chirag Patel, Prakashkumar Patel, and One other member serve as directors at the Company.
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231GJ1992PTC018162
- Company No.
018162
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Elikem Pharmaceuticals Private Limited offer?
Elikem Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutritional Supplements, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Antiparasitic Drug, Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, TB, Tumor & Cancer Drugs.
Who are the key members and board of directors at Elikem Pharmaceuticals?
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Chirag Patel ![]() | Director | 01-Apr-2005 | Current |
Pratik Patel ![]() | Director | 01-Apr-2005 | Current |
Prakashkumar Patel ![]() | Director | 01-Apr-2010 | Current |
Vasantbhai Raval ![]() | Director | 16-Jun-2014 | Current |
Financial Performance of Elikem Pharmaceuticals.
Elikem Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.15% increase. The company also saw a substantial improvement in profitability, with a 41.95% increase in profit. The company's net worth Soared by an impressive increase of 25.24%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Elikem Pharmaceuticals?
In 2022, Elikem Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹38.60 M
₹13.52 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 3.16 Cr
- Sidbi : 0.70 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
29 Jul 2023 | Hdfc Bank Limited | ₹2.50 M | Open |
26 Sep 2022 | Hdfc Bank Limited | ₹0.90 M | Open |
09 Aug 2021 | Sidbi | ₹7.00 M | Open |
30 Nov 2020 | Hdfc Bank Limited | ₹2.82 Cr | Open |
02 Jun 2020 | Sidbi | ₹5.00 M | Satisfied |
How Many Employees Work at Elikem Pharmaceuticals?
Unlock and access historical data on people associated with Elikem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Elikem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elikem Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.